CN112986568A - Detection kit for rapidly diagnosing novel coronavirus antigen by colloidal gold method based on mixed antibody - Google Patents
Detection kit for rapidly diagnosing novel coronavirus antigen by colloidal gold method based on mixed antibody Download PDFInfo
- Publication number
- CN112986568A CN112986568A CN202110463016.6A CN202110463016A CN112986568A CN 112986568 A CN112986568 A CN 112986568A CN 202110463016 A CN202110463016 A CN 202110463016A CN 112986568 A CN112986568 A CN 112986568A
- Authority
- CN
- China
- Prior art keywords
- protein
- antibody
- novel coronavirus
- mixed
- detection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Abstract
A detection kit for rapidly diagnosing a novel coronavirus antigen by a colloidal gold method based on a mixed antibody comprises a bottom plate, a sample pad, a combination pad, a coating film and an absorption pad; the binding pad is loaded with a mixed capture antibody marked by colloidal gold, and the mixed capture antibody comprises an anti-novel coronavirus N protein monoclonal antibody I and an anti-novel coronavirus S protein monoclonal antibody I; the envelope is provided with a detection area and a quality control area, the detection area per square centimeter is loaded with a mixed detection antibody, the mixed detection antibody comprises an anti-novel coronavirus N protein specific monoclonal antibody II and an anti-novel coronavirus S protein specific monoclonal antibody II, the quality control area is loaded with a mixed recombinant protein, and the mixed recombinant protein comprises a recombinant IgG Fc protein I and a recombinant IgG Fc protein II. The invention has the advantages of rapid and accurate detection result, strong specificity and high sensitivity, and can obviously improve the detection rate of the novel coronary pneumonia.
Description
Technical Field
The invention belongs to the field of molecular biology detection, and relates to a kit, in particular to a detection kit for rapidly diagnosing a novel coronavirus antigen by adopting a colloidal gold method based on a mixed antibody.
Background
2019A novel coronavirus (COVID-19) was discovered in 2019 due to viral pneumonia cases, and named by world health organization in 2020, 1 month and 12 days. And middle east respiratory syndrome virus (MERS) and severe acute respiratory syndrome virus (SARS) are among the beta coronaviruses, are among zoonotic pathogens, and can cause infections from animal to human, as well as from human to human. COVID-19 contains marker proteins such as spinous process (S) protein, membrane (M) protein, and nucleocapsid (N) protein. In order to prevent the spread of the virus and obtain effective treatment, it is important to diagnose the virus quickly and accurately.
The existing detection methods for the novel coronavirus mainly comprise nucleic acid detection, antibody detection and antigen detection. Nucleic acid detection has the characteristics of early diagnosis, high sensitivity and specificity and the like, is the 'gold standard' for determining new coronary pneumonia, but needs to implement a whole set of very strict flow for sample treatment and transportation, has extremely high requirements on detection equipment, fields and operators, and is long in detection time, so that the method has certain limitation; the antibody detection is convenient and quick, the detection time is short, and the defect of missed diagnosis caused by false negative in nucleic acid detection can be overcome. However, false positive is easy to appear due to factors such as rheumatoid factors, autoantibodies or tumor cells contained in blood of individual patients, and the detection method has a certain undetected window period because the human body needs about two weeks to generate the antibodies after being infected with new coronavirus; the antigen detection has the advantages of rapid and accurate diagnosis and low requirements on equipment and personnel, so the method can be applied to early primary screening of communities, primary hospitals, airports, customs, even families and the like. However, since the novel coronavirus mainly invades the lower respiratory tract such as alveolus, the number of viruses contained in the sample from the upper respiratory tract such as nasopharynx and oropharynx is often small, and the antigen detection kit existing in the market at present usually adopts a single antigen-specific antibody as a detection reagent, so that the detection omission due to insufficient sensitivity to the antigen (viral protein) in the sample is easily caused, and false negative is caused.
Therefore, a novel diagnostic coronavirus antigen detection kit which is more convenient, rapid, accurate and effective is needed for early screening and diagnosis.
Disclosure of Invention
Aiming at various problems in the prior art, the invention provides a detection kit for rapidly diagnosing a novel coronavirus antigen by a colloidal gold method based on a mixed antibody, thereby successfully solving the technical problems of long time and low accuracy in detecting the novel coronavirus in the prior art.
The invention provides an accurate and sensitive detection kit for rapidly diagnosing a novel coronavirus antigen based on a mixed antibody, which comprises a bottom plate, a sample pad, a combination pad, a coating film and an absorption pad, wherein the sample pad, the combination pad, the coating film and the absorption pad are sequentially fixed on the bottom plate along the flowing direction of a liquid sample to be detected;
the bonding pad is loaded with 1.2-1.8 mu g/cm2The mixed capture antibody is labeled by colloidal gold, and comprises an anti-novel coronavirus N protein antibody I and an anti-novel coronavirus S protein antibody I, wherein the anti-novel coronavirus N protein antibody I is diluted to the concentration of 15-20 mu g/ml by using a coating buffer solution (10mM PBS (pH7.2)) and is uniformly mixed with a colloidal gold solution (pH7.4) for reaction to obtain a first labeled antibody; similarly, the anti-novel coronavirus S protein antibody I is diluted to the concentration of 15-20 mu g/ml by using a coating buffer solution (10mM PBS (pH7.2)) and is mixed with a colloidal gold solution (pH7.4) for reaction to obtain a second labeled antibody; mixing the first labeled antibody and the second labeled antibody according to the volume ratio of 80% to 20% to obtain the mixed capture antibody;
the coating film is provided with a detection line (T line) and a quality control line (C line), and the detection line is loaded with 2.0-2.5 mu g/cm2The mixed detection antibody comprises an anti-novel coronavirus N protein antibody II and an anti-novel coronavirus S protein antibody II, and the anti-novel coronavirus N protein antibody II and the anti-novel coronavirus S protein antibody II with the same concentration of 1.5-2.0mg/ml are mixed according to the volume ratio of 70% to 30% to obtain the mixed detection antibody;
the quality control line is loaded with 1.2-1.8 mu g/cm2The mixed recombinant protein of (1) comprises a recombinant IgG Fc protein I and a recombinant IgG Fc protein II, and the mixed recombinant protein is obtained by mixing the recombinant IgG Fc protein I and the recombinant IgG Fc protein II with the same concentration of 1.5-2.0mg/ml according to the volume ratio of 50% to 50%;
further, the coating film is a nitrocellulose film.
Further, the anti-novel coronavirus N protein antibody I is a rabbit monoclonal antibody, and the anti-novel coronavirus S protein antibody I is a human-mouse chimeric monoclonal antibody I; the anti-novel coronavirus N protein antibody II is a mouse monoclonal antibody, and the anti-novel coronavirus S protein antibody II is a human mouse chimeric monoclonal antibody II; the recombinant IgG Fc protein I is recombinant rabbit IgG Fc protein, and the recombinant IgG Fc protein II is recombinant human IgG Fc protein.
The working principle of the invention is as follows: when a proper amount of sample to be tested is added into a sample hole (sample pad) of the kit, the sample will move forward along the kit under the action of chromatography, if the sample contains the novel coronavirus, the N protein and/or S protein of the novel coronavirus is firstly combined with the anti-novel coronavirus N protein antibody I and/or the anti-novel coronavirus S protein antibody I in the mixed capture antibody marked by the colloidal gold to form immune complex. When the sample continues to move forward to reach the position of the detection line, the immune complex can be captured by an anti-novel coronavirus N protein antibody II and/or an anti-novel coronavirus S protein antibody II in a mixed detection antibody coated on the detection line (T line) in advance, so that an immune sandwich complex is formed at the position of the detection line (T line), and a macroscopic red line appears, which indicates that the novel coronavirus antigen is positive; the redundant colloidal gold antigen conjugate continuously flows to a quality control line (C line), is captured by mixed recombinant protein pre-coated on the quality control line (C line), is fixed on the C line, and appears a macroscopic red line, which indicates that the detection result is effective; if no red line appears on the quality control line (line C), the detection result is invalid, and the sample needs to be detected again by using another detection kit.
Specifically, the Anti-novel Coronavirus N protein Antibody I and the Anti-novel Coronavirus N protein Antibody II are a pair of paired antibodies capable of simultaneously binding novel Coronavirus N protein, which are respectively purchased from Beijing-Yi-Qiao Shenzhou science and technology corporation, and have the product numbers of 40143-R004 (Anti-Coronavir viral Antibody, 40143-R004 | Sino Biological https:// cn. Biological. com/antibodies/cov-nuclear adaptive 40143-R004) and 40143-MM08 (Anti-Coronavir viral Antibody, 40143-08 | Sino Biological https:// MM// cn. Biological. com/antibodies/cov-40143 MM 08); the Anti-novel Coronavirus S protein Antibody I and the Anti-novel Coronavirus S protein Antibody II are a pair of specific paired antibodies capable of simultaneously binding to a Receptor Binding Domain (RBD) of a novel Coronavirus S protein, which are respectively purchased from Beijing-sense Kanzhou science and technology Co., Ltd, and have the product numbers of 40150-D003 (Anti-Coronavir spike Antibody, 40150-D003 | Sino Biological https:// cn. Biological. com/antibodies/cov-spike-40150-D003) and 40150-D001 (Anti-Coronavir spike Neutralizing Antibody Chimera, 40150-D001 | Sino Biological https:// cn. Biological. com/antibodies/cov-spike-40150-D); the Recombinant IgG Fc Protein I and the Recombinant IgG Fc Protein II on the quality control line are purchased from Beijing Hooka science and technology Co., Ltd respectively, and the product numbers are 11047-TNAH (Recombinant Rabbit IgG Protein, HEK293 Cells, 11047-TNAH | Biological https:// cn. Biological. com/Recombinant-proteins/rat-IgG-11047-TNAH) and 10702-HNAH (Recombinant Human IgG1 Protein, HEK293 Cells, 10702-HNAH | Biological https:// cn. Biological. Recombinant-proteins/Human-IgG 1-10702-h).
The invention finally determines the optimal raw material combination and the mixing proportion thereof required by preparing the colloidal gold labeled mixed antibody, the detection line mixed antibody and the quality control line mixed protein by the inventor through a large amount of condition exploration and screening, utilizes the principle of a colloidal gold antibody sandwich method, has quick and accurate detection result, strong specificity and high sensitivity, obviously improves the detection rate of the novel coronary pneumonia, and effectively reduces the omission factor. The invention fills the blank of high-efficiency detection of novel coronavirus by immunology, and the rapidity and the simple operability of the invention are particularly suitable for transportation hubs such as customs airports, hotel hospitals and other people gathering places, thereby preventing epidemic spread as soon as possible.
Drawings
FIG. 1 shows a specific operation flow of the kit of the present invention.
FIG. 2 shows the interpretation and color development standards of the detection kit of the present invention.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer, and those not specified by specific purchasing companies were all commercial products.
Example 1
The invention provides an accurate and sensitive detection kit for quickly diagnosing a novel coronavirus antigen based on a mixed antibody, which comprises a bottom plate, a sample pad, a combination pad, a coating film and an absorption pad, wherein the sample pad, the combination pad, the coating film and the absorption pad are sequentially fixed on the bottom plate along the flowing direction of a liquid sample to be detected;
the bonding pad is loaded with 1.2-1.8 mu g/cm2The mixed capture antibody marked by colloidal gold comprises an anti-novel coronavirus N protein antibody I and an anti-novel coronavirus S protein antibody I, and is used for resisting novel coronaDiluting the baculovirus N protein antibody I with coating buffer solution (10mM PBS (pH7.2)) to the concentration of 15-20 mu g/ml, and mixing the solution with colloidal gold solution (pH7.4) for reaction to obtain a first labeled antibody; similarly, the anti-novel coronavirus S protein antibody I is diluted to the concentration of 15-20 mu g/ml by using a coating buffer solution (10mM PBS (pH7.2)) and is mixed with a colloidal gold solution (pH7.4) for reaction to obtain a second labeled antibody; mixing the first labeled antibody and the second labeled antibody according to the volume ratio of 80% to 20% to obtain the mixed capture antibody;
the coating film is provided with a detection line (T line) and a quality control line (C line), and the detection line is loaded with 2.0-2.5 mu g/cm2The mixed detection antibody comprises an anti-novel coronavirus N protein antibody II and an anti-novel coronavirus S protein antibody II, and the anti-novel coronavirus N protein antibody II and the anti-novel coronavirus S protein antibody II with the same concentration of 1.5-2.0mg/ml are mixed according to the volume ratio of 70% to 30% to obtain the mixed detection antibody;
the quality control line is loaded with 1.2-1.8 mu g/cm2The mixed recombinant protein of (1) comprises a recombinant IgG Fc protein I and a recombinant IgG Fc protein II, and the mixed recombinant protein is obtained by mixing the recombinant IgG Fc protein I and the recombinant IgG Fc protein II with the same concentration of 1.5-2.0mg/ml according to the volume ratio of 50% to 50%;
further, the coating film is a nitrocellulose film.
Further, the anti-novel coronavirus N protein antibody I is a rabbit monoclonal antibody, and the anti-novel coronavirus S protein antibody I is a human-mouse chimeric monoclonal antibody I; the anti-novel coronavirus N protein antibody II is a mouse monoclonal antibody, and the anti-novel coronavirus S protein antibody II is a human mouse chimeric monoclonal antibody II; the recombinant IgG Fc protein I is recombinant rabbit IgG Fc protein, and the recombinant IgG Fc protein II is recombinant human IgG Fc protein.
The working principle of the invention is as follows: when a proper amount of sample to be tested is added into a sample hole (sample pad) of the kit, the sample will move forward along the kit under the action of chromatography, if the sample contains the novel coronavirus, the N protein and/or S protein of the novel coronavirus is firstly combined with the anti-novel coronavirus N protein antibody I and/or the anti-novel coronavirus S protein antibody I in the mixed capture antibody marked by the colloidal gold to form immune complex. When the sample continues to move forward to reach the position of the detection line, the immune complex can be captured by an anti-novel coronavirus N protein antibody II and/or an anti-novel coronavirus S protein antibody II in a mixed detection antibody coated on the detection line (T line) in advance, so that an immune sandwich complex is formed at the position of the detection line (T line), and a macroscopic red line appears, which indicates that the novel coronavirus antigen is positive; the redundant colloidal gold antigen conjugate continuously flows to a quality control line (C line), is captured by mixed recombinant protein pre-coated on the quality control line (C line), is fixed on the C line, and appears a macroscopic red line, which indicates that the detection result is effective; if no red line appears on the quality control line (line C), the detection result is invalid, and the sample needs to be detected again by using another detection kit.
Example 2
1. Collection of samples to be tested
And (3) treating the collected sample by using a sample extracting solution as soon as possible, and if the sample cannot be detected immediately, storing the sample in a sealed manner and storing the sample at the temperature of 2-8 ℃.
2. Nasal swab collection method
10 drops of sample extraction lysate (about 0.3 ml) were added to the extraction tube and placed on a tube rack. The swab was inserted completely into the nasal cavity, and the turbinates were rubbed several times to collect mucosal epidermis. The swab is inserted into the extraction buffer and broken off, and the dropper is closed tightly.
3. Method for collecting throat swabs
10 drops of sample extraction lysate (about 0.3 ml) were added to the extraction tube and placed on a tube rack. The swab was inserted completely into the posterior pharynx, tonsils and other inflamed areas, and the turbinates were rubbed several times to collect the mucosal epidermis. The swab is inserted into the extraction buffer and broken off, and the dropper is closed tightly.
Attention points on sample processing: 1) the collected auspicious notes are treated as early as possible according to the following preparation method; 2) because the removal of cellular components reduces the sensitivity, no centrifugation is required prior to the test; 3) all specimens are at risk for infection. Please take care when handling; 4) if the collected sample is stored for a long time, 1ul of 0.1% propiolactone can be added, and the inactivation treatment is carried out after the sample is kept at the normal temperature for 4 hours.
Applicable sample preservation solution: 1) the product is not suitable for detecting virus preservation solution containing guanidine salt (VTM/UTM); the product is not suitable for detecting virus preservation solution prepared by beta mercaptoethanol; the product is suitable for detecting the virus-containing common preservation solution.
4. The specific operation method of the kit is shown in figure 1;
step 1: if the sample is stored in a refrigerated or frozen state, the sample to be tested and the required reagent are taken out from the storage condition and are balanced to room temperature (15-30 ℃). After thawing, the samples were mixed well before testing.
Step 2: when the aluminum foil bag is ready to be detected, the aluminum foil bag is opened from the tearing opening. The kit is taken out and is horizontally placed on a horizontal desktop.
And step 3: the detection kit is marked with a sample number.
And 4, step 4: add 10 drops of buffer (about 0.3 ml) to the extraction tube.
And 5: the sterile swab sample is placed in buffer. The swab is rotated for about 10 seconds while the swab head is pressed against the inner wall of the sample tube to release the antigen from the swab.
Step 6: the swab was broken off and the sterile swab shaft was discarded according to biohazard waste disposal procedures.
And 7: and screwing the bottle cap onto the sample lifting tube, and forcibly shaking the sample lifting tube to fully mix the sample and the buffer solution.
And 8: add 3 drops of solution (about 80ul) to the sample well and then start timing. And judging the result in 10-20 minutes. Do not interpret the results after 20 minutes.
Note that: do not interpret the results after 20 minutes. After observing and recording the result, please discard the detection card to avoid confusing the result judgment. If the storage needs to be kept for a long time, please take a picture of the result.
FIG. 2 shows the interpretation color standard of the detection kit of the present invention.
Positive (Positive) if 1 fluorescence line appears on both the quality control line C and the detection line T, the detection result shows that the novel coronavirus is detected, and the result shows that the novel coronavirus is Positive.
Negative, if only the quality control line C appears a fluorescent line, the detection line T does not appear a fluorescent line, which indicates that the novel coronavirus is not detected or the concentration of the novel coronavirus is below the detection limit of the product, and the result is Negative.
Invalidity if the fluorescence line is not observed in the quality control line C, the detection line T is Invalid and should be re-detected regardless of whether the detection line is displayed.
Note that the fluorescence intensity of the generated lines can be different according to the virus concentration, and the lines can be judged to be positive regardless of the depth as long as the corresponding regions have bands.
Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, which should also be construed as the scope of the appended claims.
Claims (3)
1. A detection kit for rapidly diagnosing a novel coronavirus antigen by a colloidal gold method based on a mixed antibody comprises a base plate, a sample pad, a combination pad, a coating film and an absorption pad, wherein the sample pad, the combination pad, the coating film and the absorption pad are sequentially fixed on the base plate along the flowing direction of a liquid sample to be detected, one end of the sample pad is tightly connected with one end of the combination pad, the other end of the combination pad is tightly connected with one end of the coating film, and the other end of the coating film is tightly connected with one end of the absorption pad;
the bonding pad is loaded with 1.2-1.8 mu g/cm2The mixed capture antibody marked by the colloidal gold comprises an anti-novel coronavirus N protein antibody I and an anti-novel coronavirus S protein antibody I, and the anti-novel coronavirus N protein antibody I is diluted to the concentration of 15-20 mu g/ml by using a coating buffer solution and is uniformly mixed with a colloidal gold solution to react to obtain a first marked antibody; diluting the anti-novel coronavirus S protein antibody I with a coating buffer solution to the concentration of 15-20 mu g/ml, and uniformly mixing the diluted anti-novel coronavirus S protein antibody I with a colloidal gold solution to react to obtain a second labeled antibody; mixing the first labeled antibody and the second labeled antibody according to the volume ratio of 80% to 20% to obtain the mixed capture antibody;
the coating film is provided with a detection line and a quality control line, and the detection line is loaded with 2.0-2.5 mu g/cm2The mixed detection antibody comprises an anti-novel coronavirus N protein antibody II and an anti-novel coronavirus S protein antibody II, and the anti-novel coronavirus N protein antibody II and the anti-novel coronavirus S protein antibody II with the same concentration of 1.5-2.0mg/ml are mixed according to the volume ratio of 70% to 30% to obtain the mixed detection antibody;
the quality control line is loaded with 1.2-1.8 mu g/cm2The mixed recombinant protein comprises a recombinant IgG Fc protein I and a recombinant IgG Fc protein II, and the mixed recombinant protein is obtained by mixing the recombinant IgG Fc protein I and the recombinant IgG Fc protein II with the same concentration of 1.5-2.0mg/ml according to the volume ratio of 50% to 50%.
2. The detection kit for rapid diagnosis of the novel coronavirus antigen based on the mixed antibody colloidal gold method according to claim 1, wherein the coating membrane is a nitrocellulose membrane.
3. The detection kit for rapid diagnosis of novel coronavirus antigen by mixed antibody-based colloidal gold assay according to claim 1, wherein the anti-novel coronavirus N protein antibody I is a rabbit monoclonal antibody, and the anti-novel coronavirus S protein antibody I is a human-mouse chimeric monoclonal antibody I; the anti-novel coronavirus N protein antibody II is a mouse monoclonal antibody, and the anti-novel coronavirus S protein antibody II is a human mouse chimeric monoclonal antibody II; the recombinant IgG Fc protein I is recombinant rabbit IgG Fc protein, and the recombinant IgG Fc protein II is recombinant human IgG Fc protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110463016.6A CN112986568A (en) | 2021-04-28 | 2021-04-28 | Detection kit for rapidly diagnosing novel coronavirus antigen by colloidal gold method based on mixed antibody |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110463016.6A CN112986568A (en) | 2021-04-28 | 2021-04-28 | Detection kit for rapidly diagnosing novel coronavirus antigen by colloidal gold method based on mixed antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112986568A true CN112986568A (en) | 2021-06-18 |
Family
ID=76340460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110463016.6A Pending CN112986568A (en) | 2021-04-28 | 2021-04-28 | Detection kit for rapidly diagnosing novel coronavirus antigen by colloidal gold method based on mixed antibody |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112986568A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047459A2 (en) * | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
| EP2238451A4 (en) * | 2008-01-03 | 2011-02-23 | Univ Singapore | Nanostructures, methods of preparing and uses thereof |
| CN111337689A (en) * | 2020-04-03 | 2020-06-26 | 山西医科大学 | Novel coronavirus detection kit |
| CN112280895A (en) * | 2020-05-28 | 2021-01-29 | 上海市东方医院（同济大学附属东方医院） | Kit for detecting novel coronavirus by adopting loop-mediated transcription isothermal amplification method |
| CN112415201A (en) * | 2020-08-21 | 2021-02-26 | 北京现代高达生物技术有限责任公司 | Novel coronavirus S protein and N protein joint detection colloidal gold test strip and preparation method and application thereof |
| CN112557652A (en) * | 2020-11-19 | 2021-03-26 | 安徽瀚海博兴生物技术有限公司 | Colloidal gold kit for detecting novel coronavirus by double-antibody sandwich method and preparation method thereof |
-
2021
- 2021-04-28 CN CN202110463016.6A patent/CN112986568A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047459A2 (en) * | 2003-08-04 | 2005-05-26 | University Of Massachusetts | Sars nucleic acids, proteins, antibodies, and uses thereof |
| EP2238451A4 (en) * | 2008-01-03 | 2011-02-23 | Univ Singapore | Nanostructures, methods of preparing and uses thereof |
| CN111337689A (en) * | 2020-04-03 | 2020-06-26 | 山西医科大学 | Novel coronavirus detection kit |
| CN112280895A (en) * | 2020-05-28 | 2021-01-29 | 上海市东方医院（同济大学附属东方医院） | Kit for detecting novel coronavirus by adopting loop-mediated transcription isothermal amplification method |
| CN112415201A (en) * | 2020-08-21 | 2021-02-26 | 北京现代高达生物技术有限责任公司 | Novel coronavirus S protein and N protein joint detection colloidal gold test strip and preparation method and application thereof |
| CN112557652A (en) * | 2020-11-19 | 2021-03-26 | 安徽瀚海博兴生物技术有限公司 | Colloidal gold kit for detecting novel coronavirus by double-antibody sandwich method and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111024954A (en) | Colloidal gold immunochromatography device for combined detection of COVID-19 antigen and antibody and use method thereof | |
| CN111233985A (en) | Preparation method of novel coronavirus IgA antibody rapid detection test strip | |
| US11789020B2 (en) | Neutralizing antibody testing and treatment | |
| CN111999492A (en) | Colloidal gold immunochromatography detection card for combined detection of COVID-19N antigen and S protein antibody | |
| CN112798795A (en) | Assays for detecting blocking analytes | |
| CN108267577A (en) | A kind of EV71 viruses IgA antibody test strip | |
| US20220244258A1 (en) | Assay For Neutralizing Antibody Testing And Treatment | |
| US10006914B2 (en) | Rapid test for the qualitative and/or quantitative analysis of antibodies against human papilloma viruses (HPV) present in body fluid, and device for carrying out the rapid test | |
| US11668710B2 (en) | Assays for the detection of a blocking analyte | |
| CN106645714B (en) | EV71 virus IgA antibody test strips and its application | |
| US10684275B2 (en) | Methods and compositions for obtaining a tuberculosis assessment in a subject | |
| CN113189333A (en) | Kit containing quantum dot immunofluorescence detection reagent strip and application of kit | |
| CN112986568A (en) | Detection kit for rapidly diagnosing novel coronavirus antigen by colloidal gold method based on mixed antibody | |
| Shao | Accurate interpretation of SARS-CoV-2 antigen detection by immunochromatography | |
| CN113624977A (en) | Diagnostic method for SARS-CoV-2 infection | |
| CN112611869A (en) | Novel reagent strip for detecting coronavirus and novel coronavirus detection kit comprising same | |
| US20240133896A1 (en) | Rapid processing and direct testing of saliva biomarkers | |
| US20220205998A1 (en) | Assay for neutralizing antibody testing and treatment | |
| WO2022271980A1 (en) | Rapid processing and direct testing of saliva biomarkers | |
| WO2022141394A1 (en) | Non-invasive sampling test kit for testing sars-cov-2 antibody, and test method therefor | |
| Gupta et al. | Correlation of COVID-19 antigen test and CBNAAT results at a single tertiary care hospital in North India: an experience | |
| US20230152315A1 (en) | Kit for testing covid-19 antigen and method for testing same | |
| US20220252588A1 (en) | Neutralizing antibody testing and treatment | |
| CA3195793A1 (en) | Sars-cov-2 antigen lateral flow assay detection device and methods for using the same | |
| CN106153902B (en) | People's Brucella IgG antibody detection kit and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210618 |